Not provided
Not provided
Not provided
Not provided
The funding period for the study has ended.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open, pilot, dose-escalation study of glyceryl trinitrate (GTN, Nitroglycerin) administered by paramedics in the field within 2 hours of symptom onset to 45 severely hypertensive stroke patients. The primary objective of the study is to evaluate the feasibility, safety, and physiologic efficacy of field-initiated glyceryl trinitrate in achieving modest reduction of blood pressure. Patients with acute stroke will be identified in the field by paramedics who have received training in basic and advanced cardiac life support, stroke recognition, and specific procedures relevant to the proposed study. Physician-investigators will obtain informed consent for each subject for study entry after cellular phone contact with paramedics. Paramedics will initiate antihypertensive treatment by applying transdermal GTN patch in the first two dose-tiers, and administering a single sublingual GTN metered spray followed by application of the transdermal system in the last dose tier. The sites involved in the study will be emergency medical services rescue ambulances and 8 receiving Stroke Center hospitals in Orange County, California, USA.
The central aim of this phase 2a study is to identify a regimen of paramedic initiated glyceryl trinitrate antihypertensive therapy in acute stroke patients that is safe, is technically effective in modestly lowering blood pressure, and is optimal to advance to a pivotal trial. The study design is an open-label dose escalation study with three dose tiers,. It is anticipated that the trial will identify the most promising prehospital GTN regimen to advance to a pivotal, placebo-controlled, phase 3 trial.
Primary Hypothesis: Prehospital glyceryl trinitrate treatment reduces severely hypertensive blood pressure elevation by ED arrival.
The primary study endpoint to test this hypothesis will be the mean change in SBP from pre-treatment to ED arrival.
Secondary Hypotheses:
Prehospital glyceryl trinitrate treatment reduces severely hypertensive blood pressure elevation at early post-arrival timepoints and increases the proportion of patients with target blood pressure at ED arrival and early post-arrival timepoints.
The secondary study endpoints analyzed to test these hypotheses will be: 1) mean change in SBP from pre-treatment to 30 minutes after ED arrival and 60 minutes after ED arrival; and 2) the proportion of patients with SBP < 180 mm Hg at ED arrival, 30, and 60 minutes after arrival.
Prehospital initiation of glyceryl trinitrate in the first 2 hours for severely hypertensive patients with stroke is feasible and safe.
Safety of GTN in the first 2 hours for severely hypertensive stroke patients will be assessed by analysis of serious adverse events, neurologic change, and mortality. We hypothesize that initiation of treatment of the patients in the field will be associated with a favorable side effect profile and without severe blood pressure lowering to les than 120 mm Hg systolic.
Successful completion of the study will demonstrate feasibility to recruit hypertensive stroke participants and initiate GTN therapy in the field by paramedics.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dose Tier 1 | Experimental | Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal |
|
| Dose Tier 2 | Experimental | Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal |
|
| Dose Tier 3 | Experimental | Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Glycerly Trinitrate | Drug | 5mg/24hour (0.2mg/hour) transdermal |
|
| Measure | Description | Time Frame |
|---|---|---|
| Participants With Systolic Blood Pressure Change of 8mmHg or More | The mean change in blood pressure was measured in the Emergency Department approximately 15 minutes after application of the treatment | Baseline, 15 minutes after treatment |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Participants Experiencing Serious Adverse Events | 90 days after enrollment | |
| Participants Exhibiting Neurological Deterioration as Indicated by a Two-point or Greater Worsening in the Glasgow Coma Scale | The Glasgow Coma Scale (GCS) score measures level of consciousness in eye, motor, and verbal components. At least one point is given in each category. The scale ranges from 3 to 15, with 3 indicating deep unconsciousness and 15 indicating consciousness is not impaired. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Los Alamitos Medical Center | Los Alamitos | California | 90720 | United States | ||
| FAST-MAG Clinical Trial Coordinating Center |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Dose Tier 1 | Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal Glycerly Trinitrate: 5mg/24hour (0.2mg/hour) transdermal |
| FG001 | Dose Tier 2 | Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal Glycerly Trinitrate: 10mg/24hour (0.4mg/hour) transdermal |
| FG002 | Dose Tier 3 | Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN Glycerly Trinitrate: 10mg/24hour (0.4mg/hour) transdermal Glycerly Trinitrate: 0.4 mg sublingual single metered spray |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
The trial was stopped early due to slow enrollment. A pragmatic, low cost study, the lesser frequency of touchpoints between study staff and paramedics seemed to result in paramedics not reliably recalling in time that the study was available to offer to appropriate patients. Due to small sample size, some allocation cells had zero patients.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Dose Tier 1 | Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal Glycerly Trinitrate: 5mg/24hour (0.2mg/hour) transdermal |
| BG001 | Dose Tier 2 | Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal Glycerly Trinitrate: 10mg/24hour (0.4mg/hour) transdermal |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Participants With Systolic Blood Pressure Change of 8mmHg or More | The mean change in blood pressure was measured in the Emergency Department approximately 15 minutes after application of the treatment | Posted | Count of Participants | Participants | Baseline, 15 minutes after treatment |
|
|
90 days after enrollment
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Dose Tier 1 | Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal Glycerly Trinitrate: 5mg/24hour (0.2mg/hour) transdermal |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Death | Vascular disorders | Systematic Assessment |
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Nerses Sanossian, MD | Keck School of Medicine of USC | 323-442-7793 | nsanossi@usc.edu |
Not provided
| ID | Term |
|---|---|
| D002543 | Cerebral Hemorrhage |
| D000083242 | Ischemic Stroke |
| D020521 | Stroke |
| ID | Term |
|---|---|
| D020300 | Intracranial Hemorrhages |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005996 | Nitroglycerin |
| ID | Term |
|---|---|
| D009574 | Nitro Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Glycerly Trinitrate | Drug | 10mg/24hour (0.4mg/hour) transdermal |
|
|
| Glycerly Trinitrate | Drug | 0.4 mg sublingual single metered spray |
|
|
| Baseline, One hour after enrollment |
| Participants With Systolic Blood Pressure Less Than 120 mm/Hg | 24 hours after enrollment |
| Los Angeles |
| California |
| 90024 |
| United States |
| BG002 | Dose Tier 3 | Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN Glycerly Trinitrate: 10mg/24hour (0.4mg/hour) transdermal Glycerly Trinitrate: 0.4 mg sublingual single metered spray |
| BG003 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
|
| Other Pre-specified | Participants Experiencing Serious Adverse Events | Posted | Count of Participants | Participants | 90 days after enrollment |
|
|
|
| Other Pre-specified | Participants Exhibiting Neurological Deterioration as Indicated by a Two-point or Greater Worsening in the Glasgow Coma Scale | The Glasgow Coma Scale (GCS) score measures level of consciousness in eye, motor, and verbal components. At least one point is given in each category. The scale ranges from 3 to 15, with 3 indicating deep unconsciousness and 15 indicating consciousness is not impaired. | Posted | Count of Participants | Participants | Baseline, One hour after enrollment |
|
|
|
| Other Pre-specified | Participants With Systolic Blood Pressure Less Than 120 mm/Hg | Posted | Count of Participants | Participants | 24 hours after enrollment |
|
|
|
| 2 |
| 4 |
| 0 |
| 4 |
Not provided
Not provided
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |